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Original article

Correlation of Positron Emission Tomography/
Computed Tomography Scan with Smoking, Tumor
Size, Stage and Differentiation in Head and Neck
Cancer Patients
Jordan L. Pleitz, Partha Sinha1, Emily V. Dressler2, Rony K. Aouad
Departments of Otolaryngology ‑ Head and Neck Surgery, 1Nuclear Medicine and 2Biostatistics, University of Kentucky,
Lexington, KY 40536, USA

Abstract
The goal of this study was to identify associations between positron emission tomography/computed tomography (PET/CT)
maximum standardized uptake value (SUVmax) in patients presenting with head and neck squamous cell carcinoma (SCC)
with tumor site, size, histologic differentiation, smoking, and diabetes. Charts of patients with oropharyngeal and laryngeal SCC
who underwent 18F‑fluorodeoxyglucose PET/CT scans were reviewed between May 2007 and August 2013. Statistical analyses
included modeling log‑transformed SUVmax values by tumor site, size, histologic differentiation, smoking status, and diabetes
using unadjusted linear regressions. Differences were considered statistically significant for P < 0.05. A total of 111 patients
(54 with oropharynx and 57 with larynx cancers) were included, 83 men and 28 women with an average age of 57.5 years old.
There was a significantly higher pack‑year smoking history (P = 0.005) in the larynx cancer group. While tumor T‑stage was
found to be significantly different (P < 0.0001), there was no difference in tumor size between the two groups: 3.16 cm and
3.58 cm in the oropharynx and larynx, respectively (P = 0.55). In the oropharynx cohort, SUVmax was associated with both
tumor size (P = 0.0001) and stage (P < 0.0002). Interestingly, SUVmax differed by tumor differentiation in the larynx (P = 0.04)
but not the oropharynx (P = 0.71). Finally, there was no significant difference in SUVmax relative to diabetes and smoking status.
PET/CT SUVmax correlated with both tumor size and stage in oropharyngeal cancer patients, and it correlated only with tumor
differentiation but not the size or stage in the larynx. There were no significant differences in SUVmax by diabetes or smoking status.
Keywords: Larynx cancer, maximum standardized uptake value, oropharynx cancer, positron emission tomography/computed
tomography, smoking, tumor differentiation

Introduction
Positron emission tomography (PET) has gained
acceptance as a useful tool in the evaluation and
management of head and neck squamous cell
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carcinoma (HNSCC). [1] It relies on radiolabeled
18
F‑fluorodeoxyglucose (18F‑FDG), a glucose analog
that is transported into, but not metabolized by,
actively dividing cells. Increased mitotic activity, and
thus increased 18F‑FDG uptake, underlies the ability of
PET to detect tissues proliferating at an increased rate.
18
F‑FDG uptake within a region of interest is reported
as standardized uptake value (SUV), which accounts
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for injected activity level, incubation time, and patient
height and weight. PET/computed tomography (CT)
scans combine PET with low‑dose CT images, thus
providing both physiologic and anatomic information
within the head and neck.
The use of 18 F‑FDG PET/CT for initial HNSCC
staging, assessment of tumor response to therapy, and
posttreatment surveillance has become increasingly
common in clinical practice.[1] Yoon et al. demonstrated
the superiority of 18F‑FDG PET/CT over CT, magnetic
resonance imaging, and ultrasonography in evaluating
pretreatment locoregional tumor spread in HNSCC.[2] The
usefulness of whole‑body 18F‑FDG PET/CT in detecting
distant metastatic disease has also been shown.[3] In
a recent meta‑analysis of 2335 patients, Gupta et al.
demonstrated the ability of 18 F‑FDG PET/CT to
determine posttreatment tumor response, especially
with studies performed more than 12 weeks following
completion of therapy.[4] Paes et al. described the ability
18
F‑FDG PET/CT to detect the perineural spread of
HNSCC. [5] In his study of 63 consecutive HNSCC,
Schwartz et al. found an association between baseline
primary tumor FDG SUV and HNSCC outcomes.[6]
Furthermore, Higgins et al. demonstrated a negative
correlation between pretreatment primary tumor SUV
and 2‑year disease‑free survival.[7]
The association of 18F‑FDG PET/CT findings with
specific HNSCC tumor characteristics is a recent topic of
interest.[8] The primary goal of this study was to correlate
PET/CT maximum SUV (SUVmax) of index lesions
in patients presenting with HNSCC with tumor site,
size, and histologic differentiation. The relationship of
SUVmax with patient smoking status and diabetes was
also investigated.

Materials and Methods
Collection of study data occurred following approval by
the Institutional Review Board. The principle investigator
retrospectively reviewed the charts of all patients initially
diagnosed with HNSCC at our institution between
May 2007 and August 2013. Exclusion criteria consisted
of prior head and neck cancer treatment, incomplete
patient records, and inadequate quality of the CT or
PET/CT scans. Patients were divided based on tumor
location, including oropharynx primary tumors and
larynx primary tumors.
Gathered chart information included patient gender, age,
pack‑year smoking history, smoking status at the time of
PET/CT, and the presence of diabetes. Tumor‑specific
variables, including location, T‑stage, tumor size,
differentiation, and locoregional spread were analyzed
using pretreatment diagnostic CTs performed nearest the
52

time of PET/CT. The tumor size was defined as the greatest
tumor dimension (cm) measured in one of the three
planes (axial, sagittal, or coronal). Histopathologic analyses
were performed on specimens obtained using pretreatment
biopsies and primary surgical excisions, when available.
All pathologic specimens were formalin‑fixed and stained
using hematoxylin and eosin. Tumor differentiation was
classified as well, moderate, or poor. The CT scans were
excluded if they were low quality, thicker than 3 mm and
the measurements were difficult to be made.
All patients scanned at our institution underwent
pretreatment 18 F‑FDG PET/CT with a Biograph
TruPoint 6 scanner (Siemens Healthcare, Germany)
using lutetium oxyorthosilicate crystals. Scans were
performed in two‑dimensional mode. Before scanning,
patients fasted at least 6 h (with the exception of water).
Blood glucose levels were determined before injection
of 18F‑FDG. Scans were not performed on patients with
glucose levels >200 mg/dL. Patients were weighed
immediately before tracer injection. Following tracer
injection, patients were given 10 mL gastrografin oral
contrast per institutional guidelines. No intravenous
contrast was used.
After voiding, patients underwent low‑dose head and
neck CT (256 × 256 matrix, 1.5 mm slice thickness). PET
imaging of the head and neck (256 × 256 matrix, 1.5 mm
slice thickness) was performed immediately thereafter.
Two‑bed positions were used, with an emission time
of 5 min per position. Following this, “eyes‑to‑thigh”
supine imaging was performed using low‑dose,
nonbreath holding CT (256 × 256 matrix, 3 mm slice
thickness) followed by PET (256 × 256 matrix, 1.5 mm
slice thickness). Seven bed positions were used, with an
emission time of 3 min per position.
Somaris 5 software (Siemens Healthcare, Germany) with
two iterative passes was used for image reconstruction.
Images were interpreted by board‑certified nuclear
medicine physicians using a Syngo MMWP VE36A
Workstation (Siemens Healthcare, Germany). Primary
tumors were assessed with zoomed head and neck
images. Images were reviewed in axial, coronal, and
sagittal planes. SUVmax of lesions were calculated
in three‑dimensional by manually placing a region
of interest in one plane to encompass the entire
lesion [Figure 1]. Automated computer generated planes
in the other two planes were then reviewed and adjusted
if necessary to ensure that the entire tumor volume
was included in all three planes and no physiologic
structure with increased uptake (e.g., salivary glands)
was included. SUV calculations were based on body
volume (derived from patient weight), injected activity,
and incubation time. Corrections for lean body mass
were not made.
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Table 1: Patients characteristics
Oropharynx (n=54)

Figure 1: An example of maximum standardized uptake value of a
left oropharynx tumor

All histopathologic and radiographic findings were
reviewed at multidisciplinary tumor board and
approved by our neuroradiologists and head and neck
pathologists before their respective reports signed.
Statistical analysis correlating SUVmax with current
smoking status, serum glucose level, T‑stage, tumor size,
and tumor differentiation was performed. The primary
endpoint of SUVmax was log transformed to allow for
parametric comparisons between cancer types using
Fisher’s exact tests and 2‑sample t‑tests for categorical
and continuous outcomes, respectively. Differences in
log mean SUVmax between various demographic and
clinical variables were considered in subsets of larynx
or oropharynx cancer types. Strategies included linear
regression models and Pearson correlations stratified
by cancer type. Mean least square regression estimates
with standard deviation (SD) of log SUVmax by
categories are presented with corresponding P values.
Differences were considered statistically significant
for P < 0.05.

Results
A total of 111 patients were included in the study, and
characteristics are presented in Table 1. 57 patients
(41 males, 16 females) were included in the larynx
cancer cohort whereas 54 patients (42 males, 12 females)
were included in the oropharynx cohort. Mean age was
57.46 years (SD 8.35) and 60.06 (SD 8.74) in the larynx
and oropharynx groups, respectively (P = 0.11). Mean
smoking history was 33.13 pack‑years (SD 38.61) in
the oropharynx cohort and 53.47 pack‑years (SD 34.65)
in the larynx cohort (P = 0.005). In the oropharynx
group, 18 patients (34%) were current smokers
whereas 20 patients (37.7%) had previously quit
and 15 patients (28.3%) never smoked. In the larynx
group, 37 patients (66.1%) were current smokers

Gender
Men
Women
Age (years)
Smoking
Current
Previous
Never
Pack/year
T‑stage
T1
T2
T3
T4
Staging
I-II
III-IV
Size (cm)
Glucose
SUVmax (log
transformed)

Larynx (n=57)

42
12
60.06

77.78%
22.22%
SD: 8.74

41
16
57.46

71.93%
28.07%
SD: 8.35

18
21
15
33

33.33%
38.88%
27.77%

37
14
5
53.5

64.91%
24.56%
8.77%

8
21
3
22
2
52
3.16
100.1
2.52

Difference
between
groups (P)

0.11
0.002

0.005

2
8
25
22
3.70%
96.30%
SD: 1.14
SD: 16.61
SD: 0.40

5
8.77%
52
91.23%
3.58 SD: 1.39
102.2 SD: 20.41
2.50 SD: 0.40

0.09
0.55
0.87

SD: Standard deviation; SUVmax: Maximum standardized uptake value

whereas 14 patients (25%) had previously quit and
5 patients (8.9%) never smoked. Smoking status was
unknown in one patient for both the oropharynx cancer
and larynx cancer cohorts. There was a significant
difference in smoking status between the two groups
(P = 0.002).
Oropharynx T‑staging was as follows: T1‑tumors
(n = 8, 14.8%), T2‑tumors (n = 21, 38.9%), T3‑tumors
(n = 3, 5.6%), and T4‑tumors (n = 22, 40.7%). Larynx
T‑staging was as follows: T1‑tumors (n = 2, 3.5%),
T2‑tumors (n = 8, 14%), T3‑tumors (n = 25, 43.9%), and
T4‑tumors (n = 22, 38.6%). Tumor T‑staging between the
two groups was significantly different (P < 0.0001). Mean
oropharynx tumor size was 3.16 cm (SD 1.14) whereas
mean larynx tumor size was 3.58 cm (SD 1.39). There
was no significant difference in tumor size between the
two groups (P = 0.09).
Overall log transformed mean SUVmax was 2.52
(SD 0.40) in the oropharynx cohort and 2.50 (SD 0.40) in
the larynx cancer cohort (P = 0.87). Scatter plots with the
linear regression estimate plotted for the log transformed
SUVmax by type are shown in Figures 2 and 3. In the
oropharynx group, SUVmax is significantly associated
with both tumor size (P < 0.0001) and stage (P = 0.0002).
In the larynx group, there was no significant difference in
SUVmax based on tumor size (P = 0.38) or stage (P = 0.25).
Interestingly, SUVmax significantly is associated
with larynx tumor differentiation (P = 0.04) but
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not the oropharynx (P = 0.71). Furthermore, there
was no significant difference between SUVmax,
diabetes (P = 0.21 and P = 0.86) and smoking status
(P = 0.99 and P = 0.56) in both groups, respectively. Model
estimates for SUVmax are shown in Table 2.

Discussion
The use of 18 F‑FDG PET/CT for initial HNSCC
staging, assessment of tumor response to therapy, and
posttreatment surveillance has become increasingly
common in clinical practice.[1] Numerous studies have

shown the superiority of the PET/CT in determining
pretreatment locoregional spread,[2] distant metastasis,[3]
and posttreatment response in SCC of the head and neck
of the head and neck.[4]
The primary goal of this study was to correlate PET/CT
SUVmax with HNSCC tumor site, size, and histologic
differentiation. Interestingly, this study showed that
SUVmax correlated with tumor size (P < 0.0001)
and stage (P < 0.0002) in the oropharynx only. It is
important to note that the T‑stage in the larynx does not
Table 2: Associations with log transformed
maximum standardized uptake value for larynx and
oropharynx cancer
Oropharynx
SUVmax SD
P
estimate

Figure 2: Scatter plot with the linear regression estimate plotted for
the log transformed maximum standardized uptake value by type

Tumor size (cm)
Stage
T1
T2
T3
T4
Differentiation
Poor
Moderate
Well
Smoking
Current
Former
Never
Diabetes
Yes
No

Larynx
SUVmax SD
estimate

P

0.23

0.04

0.0001*

0.03

0.04

0.38

2.08
2.44
3.03
2.66

0.13
0.07
0.19
0.07

0.0002*

2.58
2.42
2.41
2.63

0.28
0.14
0.08
0.09

0.25

2.54
2.46
2.67

0.07
0.09
0.4

0.71

2.52
2.53
1.94

0.08
0.07
0.22

0.04*

2.52
2.51
2.51

0.1
0.09
0.11

0.99

2.5
2.56
2.33

0.07
0.11
0.18

0.56

2.66
2.48

0.13
0.06

0.21

2.47
2.51

0.17
0.06

0.86

*Unadjusted linear regression model estimates. SD: Standard deviation;
SUVmax: Maximum standardized uptake value

Figure 3: Scatter plot with the linear regression estimate plotted for the log transformed maximum standardized uptake value by type for the
whole‑group
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follow the size of the tumor but the subsites involved
by the tumor and the mobility of the vocal cord: A 1
cm tumor of the base of the tongue is staged a T1 of the
oropharynx, but it could be staged a T3 of the larynx if
the vocal cord is immobile. Similar results were found
by Haerle et al.[8] in their study of newly diagnosed
HNSCC patients where a positive association of
SUVmax was found with T‑classification. However,
unlike Haerle’s study, we also observed a correlation
between SUVmax and tumor histologic differentiation
in the larynx: The higher the SUV, the higher tumor
differentiation.
The secondary endpoint of this study was to examine
the association between SUVmax and smoking history
of the head and neck cancer patients. The relationship
of SUVmax and tobacco usage is poorly reported in the
literature. Na et al.[9] studied the association between
smoking history, SUV, and nodal disease in nonsmall‑cell
lung cancer and he found the SUV of nonsmokers was
less than the SUV of smokers (P < 0.001). Our results
did not demonstrate a significant correlation between
SUVmax and smoking status in either oropharynx or
larynx cancer patients. To the best of our knowledge,
this is the first study correlating SUVmax and smoking
status in HNSCC.
Despite those interesting findings, our study has some
limitations. The study is retrospective by design. In
addition, pack‑year, which is considered to be the
standard way of measuring the smoking history,
was determined based on patient responses recorded
during their initial presentation to the clinic. This
measure may have been flawed given its subjectivity
and reliance on “rounded” numbers. Future studies
may potentially overcome this by analyzing objective
measures of tobacco use (e.g., serum cotinine levels).
In addition, it is challenging to compare oropharynx
and larynx cancers SUVmax with regards to T‑size
given the differences in TNM staging between the two
subsites. A large tumor in the oropharynx may only
be considered a T1–T2 (<4 cm without deep muscle
invasion) while a small tumor of the larynx with
immobility of the vocal fold is a T3. Furthermore, this
study did include several tumors <1.5 cm, in which
accuracy of SUVmax decreases.[1] The effect of these
inaccuracies was likely small, as these tumors only
accounted for five patients in the oropharynx cohort
and three patients in the larynx cohort. Finally, the
method we used to measure the size of the tumor may
be another source of weakness despite all our efforts
to minimize this human error.

Conclusion
Our study showed that SUVmax correlated with both
tumor size and stage in oropharyngeal cancers, but not
histologic differentiation unlike in the larynx where
SUVmax correlated with tumor differentiation but not with
size and stage of the tumor. We did not find any correlation
between SUVmax and diabetes or smoking status. These
findings are sure interesting, however future research
is needed to help determine the clinical significance of
PET/CT’s SUVmax in head and neck cancer, especially
in counseling patients before their treatment.
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